This study supports and provides additional cases and genomic data for the proposal by Ghasemi et al. that the MYCN amplified spinal cord ependymomas (SP-EPN-MYCN) be considered as a unique clinicopathological category within the broader group of SP-EPN [5]. The gene discussed is MYCN; the disease is spinal cord ependymoma.